Cargando…

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry

To assess the efficacy of radioimmunotherapy (RIT) with (90)yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hohloch, Karin, Windemuth-Kieselbach, Christine, Zinzani, Pier Luigi, Cacchione, Roberto, Jurczak, Wojciech, Suh, C., Trümper, Lorenz, Scholz, Christian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196943/ https://www.ncbi.nlm.nih.gov/pubmed/32125469 http://dx.doi.org/10.1007/s00277-020-03956-0

Ejemplares similares

Perspectives on metals-based radioimmunotherapy (RIT): moving forward
por: White, Jordan M., et al.
Publicado: (2021)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
por: Hauswald, H., et al.
Publicado: (2018)

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution
por: Andrade Campos, Marcio Miguel, et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
por: Schoof, Nils, et al.
Publicado: (2009)

Putting the Rit in cellular resistance: Rit, p38 MAPK and oxidative stress
por: Cai, Weikang, et al.
Publicado: (2013)

Controversies in the Treatment of Peripheral T-cell Lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2020)

P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.
por: Ladetto, M., et al.
Publicado: (2022)

Bon Dieu rit : roman /
por: Saint-Amand, Edris
Publicado: (1988)

Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers
por: Garambois, Véronique, et al.
Publicado: (2004)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)
por: Zettl, Florian, et al.
Publicado: (2020)

Isolation, Identification, Whole-Genome Sequencing, and Annotation of Four Bacillus Species, B. anthracis RIT375, B. circulans RIT379, B. altitudinis RIT380, and B. megaterium RIT381, from Internal Stem Tissue of the Insulin Plant Costus igneus
por: Polter, Steven J., et al.
Publicado: (2015)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Aeromonas hydrophila RIT668 and Citrobacter portucalensis RIT669—Potential Zoonotic Pathogens Isolated from Spotted Turtles
por: Thomas, Seema G., et al.
Publicado: (2020)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Invasive tracheobronchial aspergillosis developed during radioimmunotherapy for malignant lymphoma
por: Sato, Shuku, et al.
Publicado: (2018)

Isolation, Whole-Genome Sequencing, and Annotation of Three Unclassified Antibiotic-Producing Bacteria, Enterobacter sp. Strain RIT 637, Pseudomonas sp. Strain RIT 778, and Deinococcus sp. Strain RIT 780
por: Schroeter, Marissa N., et al.
Publicado: (2021)

Oncogenic RIT1 mutations in lung adenocarcinoma
por: Berger, A H, et al.
Publicado: (2014)

Lymphoma immunotherapy
por: Zinzani, Pier Luigi
Publicado: (2018)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Physiologically Based Pharmacokinetic Modeling Is Essential in (90)Y-Labeled Anti-CD66 Radioimmunotherapy
por: Kletting, Peter, et al.
Publicado: (2015)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
por: Wu, Chenglin, et al.
Publicado: (2016)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
por: Tilch, Marie-Kristin, et al.
Publicado: (2022)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy
por: Takahashi, Miwako, et al.
Publicado: (2014)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
por: Jin, L, et al.
Publicado: (2011)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6feni4n04nfhob68dnepgeoejc